This antibody is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. The antibody is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids
Chen, Haizhang, et al. "Detection and functional resolution of soluble immune complexes by an FcγR reporter cell panel." EMBO Molecular Medicine 14.1 (2022): e14182. https://doi.org/10.15252/emmm.202114182
This study focuses on developing a robust and scalable test system to detect and quantify the bioactivity of soluble IgG immune complexes (sICs). These complexes play a significant role in autoimmune diseases such as systemic lupus erythematosus (SLE). The researchers created a comprehensive panel of reporter cell lines that enable the quantification of sIC reactivity through ELISA or flow cytometry. This system identified FcγRIIA(H) and FcγRIIIA as the most sensitive receptors to sICs, allowing for the detailed analysis of sIC size and stoichiometry. The assay has shown predictive capabilities regarding the severity of SLE by analyzing sera from patients and mouse models, providing a sensitive tool to evaluate sICs in various settings.
Creative Biolabs contributed to this study by providing the pharmaceutical-grade humanized monoclonal IgG1 antibody rituximab (Cat# TP-082CL). Rituximab was crucial for generating soluble immune complexes (sICs) in the experiments. The study utilized recombinant CD20, obtained as a peptide containing the binding region of rituximab, to form these sICs. This setup allowed the researchers to create and analyze the immune complexes accurately. The high-quality rituximab provided by Creative Biolabs enabled the development of a sensitive and specific assay for detecting Fcγ receptor activation, which was essential for the study's success in evaluating the bioactivity and size of sICs.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-1117z | Mouse Anti-IGHG1 Recombinant Antibody (clone 5C2) | FC, IF, IHC, WB | Mouse IgG1, κ |
MOB-034LC | Mouse Anti-IGHG1 Recombinant Antibody (clone YC121) | ELISA, WB, IHC | Mouse IgG |
VS3-FY2150 | Rabbit Anti-IGHG1 Recombinant Antibody (clone R29-3R-6) | WB | Rabbit IgG |
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TP-082CL, RRID: AB_3112049)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.